Cerus Corporation logo

Cerus Corporation (CERS)

Market Closed
3 Jun, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
2. 6650
-0.035
-1.3%
$
565.04M Market Cap
- P/E Ratio
- Div Yield
318,658 Volume
-0.1 Eps
$ 2.7
Previous Close
Add Transaction
Day Range
2.625 2.745
Year Range
1.15 3.15
Want to track CERS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231 million, which would imply promising 10%-12% YoY growth. IFC volumes rose about 120% YoY, making it the clearest current growth vertical beyond platelets.

Seekingalpha | 3 weeks ago
Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Seekingalpha | 1 month ago
Cerus's Record 2025 Sets It Up For Another Leg Higher

Cerus's Record 2025 Sets It Up For Another Leg Higher

CERS' INTERCEPT platform (kits + illuminators) is scaling globally, with record 2025 results. They've also grown their adoption across ~40 countries. INT200 received European approval and launched. They also have a US PMA filing targeted for 2026. This means CERS may soon have another hardware refresh cycle, with future kit pull-through.

Seekingalpha | 3 months ago
Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Seekingalpha | 3 months ago
Cerus: IFC Growth And RBC Optionality

Cerus: IFC Growth And RBC Optionality

CERS develops the Intercept Blood System for platelets, plasma, and IFC. These are valuable offerings for blood transfusions. CERS Intercept provides a pathogen-reduced transfusion product suite that directly address blood safety worldwide. IFC allows for room-temperature fibrinogen support that sharply reduces wasted product and turnaround times.

Seekingalpha | 6 months ago
Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript

Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript

Cerus Corporation ( CERS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Timothy Lee William Greenman - President, CEO & Chairman Vivek Jayaraman - Chief Operating Officer Kevin Green - VP of Finance & CFO Conference Call Participants Junwoo Park - Cantor Fitzgerald & Co., Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Third Quarter 2025 Earnings Conference Call.

Seekingalpha | 6 months ago
Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript

Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Kevin D. Green - VP of Finance & CFO Vivek K.

Seekingalpha | 10 months ago
Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript

Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Tim Lee - Head of Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President Conference Call Participants Josh Jennings - TD Cowen Matt Park - Cantor Fitzgerald Vidyun Bais - BTIG Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation First Quarter 2025 Earnings Conference Call.

Seekingalpha | 1 year ago
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates

Cerus (CERS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.05 per share a year ago.

Zacks | 1 year ago
Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript

Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS ) Q4 2024 Earnings Call February 20, 2025 4:30 PM ET Company Participants Noopur Liffick - Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President Conference Call Participants Joshua Jennings - TD Cowen Jacob Johnson - Stephens. Ross Osborn - Cantor Fitzgerald John Wilkin - Craig-Hallum Operator Good day, ladies and gentlemen.

Seekingalpha | 1 year ago
Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript

Cerus Corporation (CERS) Q3 2024 Earnings Call Transcript

Cerus Corporation (NASDAQ:CERS ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman - COO Kevin Green - CFO Conference Call Participants Matthew Park - Cantor Fitzgerald Colin Wells - Stifel Jacob Johnson - Stephens Joshua Jennings - TD Cowan Vidyun Bais - BTIG William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Third Quarter 2024 Earnings Conference Call.

Seekingalpha | 1 year ago
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

Cerus (CERS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.

Zacks | 1 year ago
Loading...
Load More